Atara Biotherapeutics, Inc. - 8-K Filing
Atara Biotherapeutics reported a net loss of $4.1 million for Q1 2026 compared to net income of $38.0 million in the same period last year, driven by significantly lower revenues ($0.5 million vs. $98.1 million). The company plans to resubmit its BLA for tabelecleucel after a productive FDA meeting and expects cash runway through mid-2027 based on current balances of $8.4 million in cash and $4.8 million from ATM proceeds. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ATRA